Biotech Analyst Biegler, along with Dr. Sheinei Alan, Director of Clinical Research at Inova Schar Adult Sickle Cell Program, preview Fulcrum’s upcoming PIONEER data and discuss recent developments in the treatment landscape for SCD on an Analyst/Industry conference call to be held on May 14 at 10:30 am.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Cautious Outlook for Fulcrum Therapeutics Amid Phase 1b Progress and Enrollment Uncertainties
- Hold Rating for Fulcrum Therapeutics Amid Promising Trials and Competitive Challenges
- Fulcrum Therapeutics Reports Q1 2025 Progress and Stability
- Fulcrum Therapeutics’ Positive Earnings Call Highlights
- Fulcrum Therapeutics price target lowered to $12 from $14 at Oppenheimer